Article: Zonagen Loses ED Drug Partner, Submits One-Year Study Results.

Staff Writer

Zonagen Inc. reported a mixed bag of news regarding its phentolamine-based technologies to treat sexual dysfunction.

The Woodlands, Texas-based firm said it agreed to split with Schering-Plough Corp., terminating worldwide licensing agreements covering technologies including Vasomax, Zonagen's oral therapy to treat erectile dysfunction.

"We felt it was coming," Zonagen President and CEO Joseph Podolski told BioWorld Today. "It's certainly not a good thing, but in this case, given how this market is evolving, it gives us the opportunity to shop this product again and also gives us the opportunity to shop our second and third ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!